Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpiNet-First Trial 5 in new-onset unclassified epilepsy unsuitable for sodium valproate
ACTRN12615000641594Phase 4Terminated
- Sponsor
- EpiNet Study Group
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, open-label trial in epilepsy comparing Levetiracetam monotherapy with Lamotrigine monotherapy (2 arms). Primary endpoint: Time to 12-month remission from seizures. Started May 2015; status: terminated.
02
Drugs
levetiracetamlamotrigine
03
Conditions
epilepsy
Beyond the preview
Go deeper on ACTRN12615000641594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000641594.